To present a case study of a pediatric patient with severe IgE-mediated food allergies and asthma following liver transplantation, highlighting the role of omalizumab in management.
Key Findings:
The patient achieved excellent asthma control and resumed a less restricted diet after treatment with omalizumab, indicating its potential as a therapeutic option.
Liver graft function remained stable with no graft-related adverse events over more than 5 years of follow-up, suggesting long-term safety.
Interpretation:
This case supports the long-term safety and effectiveness of omalizumab in managing severe IgE-mediated food allergies and asthma in pediatric liver transplant recipients, potentially influencing treatment strategies.
Limitations:
The study is based on a single case report, limiting generalizability to the broader population of pediatric liver transplant recipients.
No information was available regarding the donor's atopic history, which could influence the patient's allergic profile.
Conclusion:
Omalizumab may be a beneficial off-label treatment for managing severe allergic reactions and asthma in pediatric patients post-liver transplantation, warranting further investigation.
